Royalty Pharma share price logo

Royalty Pharma

NASDAQ: RPRX

Large Cap

$56.93

+0.72

(+1.28%)

as on

Royalty Pharma Stock Performance

as on October 10, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $55.97
    $57.08
    downward going graph

    1.69%

    Downside

    0.26%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $35.23
    $64.38
    downward going graph

    38.12%

    Downside

    13.09%

    Upside

    downward going graph

Royalty Pharma share price movements today

Previous Close
$56.21
Open
$56.14
Volume
2.5M
Market Cap
$32.6B
Dividend Yield
1.65%
Day's Low - High
$55.97 - $57.08
52 Week Low - High
$35.23 - $64.38

Royalty Pharma Historical Returns

1 Month Return
-3.1 %
3 Month Return
+ 0.89 %
1 Year Return
+ 58.09 %
3 Year Return
+ 111.4 %
5 Year Return
+ 60.41 %

Royalty Pharma Stock Fundamentals & Key Indicators

Check Royalty Pharma market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$32.6B

EPS (TTM)

2.41

Dividend Yield

1.65%

Quarterly Earnings Growth YOY

-0.46%

PE Ratio (TTM)

23.32

Industry PE ratio

7.28

PEG Ratio

6.79

EBITDA

1.7B

Revenue (TTM)

2.5B

Profit Margin

89.38%

Return On Equity TTM

12.25%

Royalty Pharma vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Royalty Pharma with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
StrongBuy$32.6B60.41%23.3289.38%1.65%
Neutral$78.6B-26.21%-24.69-12.57%0.00%
StrongBuy$127.6B185.06%29.0686.04%0.00%
Buy$76.4B35.73%17.6684.86%0.50%

Stock Returns calculator for Royalty Pharma Stock including INR - Dollar returns

The Royalty Pharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Royalty Pharma investment value today

Current value as on today

₹1,72,386

Returns

₹72,386

(+72.39%)

Returns from Royalty Pharma Stock

₹58,095 (+58.09%)

Dollar Impact

₹14,291 (+14.29%)

Analyst Recommendation on Royalty Pharma Stock

Based on 6 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 6 analysts, 100% of analysts recommend a 'BUY' rating for Royalty Pharma. Average target price of $65.38

Royalty Pharma Share Price Target

Get share price movements and forecasts by analysts on Royalty Pharma.

What analysts predicted

12.92%UPSIDE

Target Price

$65.38

Current Price

$56.93

Analyzed by

6 Analysts

High

$70

Target

$65.38

Low

$62

Royalty Pharma target price $65.38, a slight upside of 12.92% compared to current price of $56.93. According to 6 analysts rating.

Indian Investors' Interest in Royalty Pharma Stock

Search interest for Royalty Pharma Stock has increased by 71% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:71% versus previous 30 day period

Royalty Pharma Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
567
537
564
593
568
578
609
621
630
674
Gross Profit
567
537
564
593
568
578
609
621
629
405
Operating Income
-73
269
735
361
534
209
427
388
632
133
EBITDA
39
243
872
400
498
159
525
451
563
176
Interest Expense
44
49
66
65
65
68
79
94
93
93
Depreciation
-
-
-
-
-
-
1
1
1
1
Income Before Tax
-4
194
806
334
433
90
444
355
468
81
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
4
102
543
208
238
30
288
214
295
17
Net Profit Margin
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
99.81%
60.21%

Royalty Pharma Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1,597
1,794
1,814
2,122
2,289
2,237
2,354
2,263
2,378
Gross Profit
1,597
1,794
1,814
2,122
2,289
2,237
2,354
2,263
2,378
Operating Income
939
1,364
2,623
1,595
1,430
307
1,492
1,292
1,559
EBITDA
1,623
1,831
2,753
1,882
1,430
423
1,887
1,556
1,635
Interest Expense
247
279
268
157
166
187
187
225
307
Depreciation
33
33
23
23
22
5
-
-
3
Income Before Tax
1,343
1,517
2,461
1,701
1,241
230
1,700
1,330
1,324
Income Tax Expense
-
-
-
-
-
-
-
-
-
Net Income
1,210
1,377
2,348
975
619
42
1,134
858
770
Net Profit Margin
100.00%
100.00%
100.00%
89.12%
100.00%
100.00%
100.00%
100.00%
100.00%

Royalty Pharma Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-4
194
806
334
433
90
444
355
294
-294
Operating Cash Flow
664
658
703
742
596
363
702
827
760
686
Investing Cash Flow
-86
-893
-1,192
-505
503
-311
-958
-847
-520
-187
Financing Cash Flow
-211
1,156
-325
-257
-941
-507
562
-299
-272
-273
Change in Cash
365
921
-814
-21
158
-455
307
-320
-32
225

Royalty Pharma Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
1,343
1,517
2,461
1,701
1,241
230
1,700
1,330
1,324
Operating Cash Flow
1,418
1,618
1,667
2,034
2,017
2,143
2,987
2,768
2,489
Investing Cash Flow
-1,587
303
-2,153
-2,759
-1,870
-1,029
-2,072
-2,678
-1,614
Financing Cash Flow
-123
-1,379
-1,191
1,487
385
-944
-2,148
361
-1,185
Change in Cash
-292
542
-1,678
762
532
169
-1,233
452
-310

Global Institutional Holdings in Royalty Pharma

Check out the Institutions with significant holdings in Royalty Pharma.

Funds
Holdings
New Perspective Fund
4.41%
iShares
3.60%
Capital Income Builder
1.93%
Vanguard
1.88%
Growth Fund of America
1.24%

Royalty Pharma News & Key Events

    Insights on Royalty Pharma

    Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

    • imgPOSITIVE IMPACT

      Price Rise

      img

      In the last 1 year, RPRX stock has moved up by 58.1%

    • imgPOSITIVE IMPACT

      Revenue Rich

      img

      Revenue is up for the last 6 quarters, 568.24M → 674.14M (in $), with an average increase of 3.3% per quarter

    • imgNO EFFECT

      Against Peers

      img

      In the last 1 year, Moderna, Inc. Common Stock has given 738.6% return, outperforming this stock by 680.5%

    • imgNO EFFECT

      Against Peers

      img

      In the last 3 years, Moderna, Inc. Common Stock has given 119.0% return, outperforming this stock by 9.2%

    • imgNEGATIVE IMPACT

      Profit Down

      img

      Netprofit is down for the last 2 quarters, 294.99M → 17.88M (in $), with an average decrease of 93.9% per quarter

    About Royalty Pharma

    Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
    OrganisationRoyalty Pharma
    Headquarters110 East 59th Street, New York, NY, 10022, US
    IndustryMedical - Pharmaceuticals
    CEOPablo Legorreta

    Key Management of Royalty Pharma

    Name

    Title

    Mr. Christopher Hite

    Chairman of Partnering & Investments

    Dr. Marshall Jonathan Urist M.D., Ph.D.

    Head of Research & Investments

    Dr. James Folmar Reddoch Ph.D.

    Executive VP of Investments & Chief Scientific Officer

    Mr. George Grofik C.F.A., CPA

    Senior VP and Head of Investor Relations & Communications

    Mr. Arthur Richard McGivern J.D.

    Executive VP of Investment & Chief Legal Officer

    Mr. Pablo Legorreta

    Founder, Chairman of the Board & CEO

    Mr. Terrance P. Coyne

    Executive VP & CFO

    Mr. Greg Butz

    Executive Vice President of Partnering & Investments

    Mr. Eric Cornelius Schneider

    Senior VP & Chief Technology Officer

    Ms. Molly Sawaya

    Executive VP & Head of Human Capital

    FAQs

    What is Royalty Pharma share price today?

    Royalty Pharma share price today is $56.93 as on at the close of the market. Royalty Pharma share today touched a day high of $57.08 and a low of $55.97.

    What is the 52 week high and 52 week low for Royalty Pharma share?

    Royalty Pharma share touched a 52 week high of $64.38 on and a 52 week low of $35.23 on . Royalty Pharma stock price today i.e. is closed at $56.93,which is 11.57% down from its 52 week high and 61.60% up from its 52 week low.

    What is Royalty Pharma's market capitalisation today?

    Royalty Pharma market capitalisation is $0.03T as on .

    How to invest in Royalty Pharma Stock (RPRX) from India?

    1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
    2. Step 2: Search for Royalty Pharma on INDmoney app. Click on Buy button.

    What is the minimum amount required to buy Royalty Pharma Stock (RPRX) from India?

    Indian investors can start investing in Royalty Pharma (RPRX) shares with as little as ₹96.779998779297 or $1 (as of ) using the INDmoney app.
    For example: If you want to invest $10 or ₹967.80 in Royalty Pharma stock (as per the Rupee-Dollar exchange rate as on ). Based on Royalty Pharma share’s latest price of $56.93 as on October 10, 2026 at 8:46 am IST, you will get 0.1757 shares of Royalty Pharma. Learn more about fractional shares .

    What are the returns that Royalty Pharma has given to Indian investors in the last 5 years?

    Royalty Pharma stock has given 60.41% share price returns and 28.36% dollar appreciation to an Indian investor in the last 5 years.
    Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?